非阿片类止痛药物开发商Latigo Biotherapeutics完成1.5亿美元B轮融资，推进非阿片类止痛药物研发-动脉网

Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics

CISION 等信源发布 2025-03-17 17:00



可切换为仅中文







Financing led by funds managed by Blue Owl Capital; Senior Managing Director

由Blue Owl Capital管理的基金主导融资；高级董事总经理

Kevin Raidy

凯文·雷迪

joins Latigo's board

加入Latigo的董事会

Proceeds support advancement of company's Nav1.8 inhibitor clinical programs and development of broader pipeline

收益将支持公司Nav1.8抑制剂临床项目的进展以及更广泛产品线的开发。

THOUSAND OAKS, Calif.

加利福尼亚州千橡市

，

March 17, 2025

2025年3月17日

/PRNewswire/ -- Latigo Biotherapeutics ('Latigo'), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, today announced it has closed

/PRNewswire/ -- Latigo Biotherapeutics（“Latigo”），一家临床阶段的生物技术公司，致力于开发针对疼痛源头的最佳非阿片类止痛治疗方法，今日宣布已完成

$150 million

1.5亿美元

in a Series B financing. Proceeds from the financing will support the advancement of the company's highly selective Nav1.8 inhibitors currently in clinical development for the non-opioid treatment of pain, as well as the development of Latigo's broader pipeline.

在B轮融资中，融资所得将用于推动公司高选择性Nav1.8抑制剂的进展，该抑制剂目前正在临床开发中，用于非阿片类镇痛治疗，同时也将支持Latigo更广泛的研发管线的开发。

The financing was led by funds managed by Blue Owl Capital, with participation from Deep Track Capital, Access Biotechnology, Qatar Investment Authority, Cormorant Asset Management, Sanofi Ventures, Rock Springs Capital, UPMC Enterprises, and Kern Capital. Existing investors Westlake Village BioPartners, Foresite Capital, .

本轮融资由蓝猫头鹰资本管理的基金领投，深轨资本、Access Biotechnology、卡塔尔投资局、鸬鹚资产管理、赛诺菲风险投资、岩泉资本、UPMC企业以及Kern Capital参与。现有投资者西湖村生物合伙人、前景资本也参与其中。

5AM

早上5点

Ventures, and Alexandria Venture Investments also participated in the financing round, reaffirming their commitment to Latigo's mission to develop safer, more effective pain treatments.

风险投资公司和亚历山大风险投资公司也参与了这轮融资，重申了他们对Latigo开发更安全、更有效的疼痛治疗方法使命的支持。

'The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust portfolio of pain medicines that have the potential to transform the treatment landscape,' said

“对非阿片类止痛治疗的需求从未如此迫切，这笔资金使我们能够加速开发我们强大的止痛药物组合，这些药物有潜力改变治疗格局，”

Nima Farzan

尼玛·法尔赞

, chief executive officer of Latigo Biotherapeutics. 'We appreciate the support of our new and existing investors as we work to bring best-in-class, non-addictive pain treatments to patients.'

拉蒂戈生物治疗公司的首席执行官表示：“我们感谢新老投资者的支持，因为我们正在努力为患者带来一流的非成瘾性疼痛治疗方法。”

As part of the financing,

作为融资的一部分，

Kevin Raidy

凯文·雷迪

, senior managing director at Blue Owl Capital, has joined Latigo's board of directors. 'The field of pain management is long overdue for innovation beyond opioids, and we believe Latigo is well-positioned to advance novel, non-addictive treatments that could make a real difference for patients,' Raidy said. .

蓝鸥资本的高级董事总经理已加入Latigo的董事会。Raidy表示：“疼痛管理领域早该迎来超越阿片类药物的创新，我们相信Latigo有能力推动新型非成瘾性治疗方案的发展，这将为患者带来真正的改变。”

'We are pleased to welcome Kevin to the board. His experience in life sciences investing and strategic growth will be invaluable as Latigo continues to scale,' said

“我们很高兴欢迎凯文加入董事会。他在生命科学投资和战略增长方面的经验，将对Latigo的持续扩展起到不可估量的作用，”

Timothy P. Walbert

蒂莫西·P·沃尔伯特

, chair of Latigo's board. 'With this financing and the continued support of world-class investors, we will be able to rapidly advance our pipeline of non-opioid treatments for chronic and acute pain.'

，Latigo董事会主席。“通过这次融资以及世界级投资者的持续支持，我们将能够快速推进我们用于治疗慢性疼痛和急性疼痛的非阿片类药物的研发进程。”

About Latigo Biotherapeutics' Clinical Programs

关于Latigo Biotherapeutics的临床项目

Latigo recently reported positive Phase 1 results for LTG-001, its lead potential best-in-class non-opioid pain medicine candidate. LTG-001 is an oral, selective Nav1.8 inhibitor in development to treat acute pain at its source. In the Phase 1 first-in-human clinical trial, data showed that LTG-001 was well tolerated with rapid absorption..

Latigo最近报告了其领先的潜在最佳非阿片类止痛药物候选药物LTG-001的I期阳性结果。LTG-001是一种口服、选择性Nav1.8抑制剂，正在开发用于从源头治疗急性疼痛。在I期首次人体临床试验中，数据显示LTG-001耐受性良好，吸收迅速。

LTG-305, oral, selective Nav1.8 inhibitor, currently in Phase 1 clinical trials, is a potential best-in-class non-opioid therapeutic candidate for the treatment of chronic pain. The Phase 1 trial is designed to evaluate the safety, tolerability, and pharmacokinetics of LTG-305 in healthy volunteers through single-ascending dose and multiple-ascending dose cohorts..

LTG-305，口服选择性Nav1.8抑制剂，目前处于一期临床试验阶段，是治疗慢性疼痛的潜在最佳非阿片类治疗候选药物。一期试验旨在通过单剂量递增和多剂量递增队列评估LTG-305在健康志愿者中的安全性、耐受性和药代动力学。

About Latigo Biotherapeutics

关于Latigo生物治疗公司

Latigo Biotherapeutics is a private clinical-stage biotechnology company developing innovative non-opioid pain medicines with potential best-in-class profiles that directly target the source of pain. Latigo's goal is to provide effective, rapid-acting pain relief without the risk of addiction. For more information, please visit .

Latigo Biotherapeutics是一家私人临床阶段的生物技术公司，致力于开发创新的非阿片类止痛药物，这些药物具有潜在的同类最佳特性，能够直接针对疼痛源头。Latigo的目标是提供有效且快速缓解疼痛的治疗方案，同时避免成瘾风险。欲了解更多信息，请访问。

www.latigobio.com

or follow us on

或关注我们

领英

。

SOURCE Latigo Biotherapeutics

源拉提戈生物治疗公司

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？